תאריך רישום: July 1, 2018

מסלול הגשה: מולקולה חדשה

יצרן: CELLFORCURE, FRANCE

בעל רישום: NOVARTIS ISRAEL LTD

:ATC Code

4.1 Therapeutic indications Kymriah is indicated for the treatment of: • Paediatric and young adult patients up to and including 25 years of age with CD19+ B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse. • Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Limitation of Use: Kymriah is not indicated for treatment of patients with primary or secondary central nervous system lymphoma. • Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

תאריך רישום: January 1, 2019

מסלול הגשה: תכשיר גנרי

יצרן: LEK PHARMACEUTICALS D. D., SLOVENIA

בעל רישום: SANDOZ PHARMACEUTICALS ISRAEL LTD

N05AX12 :ATC Code

תאריך רישום: January 1, 2019

מסלול הגשה: תכשיר גנרי

יצרן: LEK PHARMACEUTICALS D. D., SLOVENIA

בעל רישום: SANDOZ PHARMACEUTICALS ISRAEL LTD

N05AX12 :ATC Code

תאריך רישום: July 1, 2018

מסלול הגשה: מולקולה חדשה

יצרן: CELLFORCURE, FRANCE

בעל רישום: NOVARTIS ISRAEL LTD

:ATC Code

4.1 Therapeutic indications Kymriah is indicated for the treatment of: • Paediatric and young adult patients up to and including 25 years of age with CD19+ B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse. • Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Limitation of Use: Kymriah is not indicated for treatment of patients with primary or secondary central nervous system lymphoma. • Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

תאריך רישום: March 28, 1993

מסלול הגשה: מולקולה חדשה

יצרן: RECIPHARM KARLSKOGA AB, SWEDEN

בעל רישום: PADAGIS ISRAEL AGENCIES LTD, ISRAEL

N01BB54 :ATC Code

4.1 Therapeutic indications Topical anesthesia for superficial dermal analgesia in connection with insertion of IV catheters, blood sampling and superficial surgical procedures.

תאריך רישום: November 1, 2018

מסלול הגשה: מולקולה חדשה

יצרן: ELI LILLY AND COMPANY, USA

בעל רישום: ELI LILLY ISRAEL LTD, ISRAEL

N02CX08 :ATC Code

4.1 Therapeutic indications Emgality is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.